N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor

US7511037B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• B. Narasimhulu Naidu · Durham, US
• Jacques Banville · St-Hubert, CA
• Francis Beaulieu · Elliot Lake, CA
• Timothy P. Connolly · Portland, US
• Mark Krystal · Leonia, US
• John D. Matiskella · Wallingford, US
• Carl Ouellet · Boucherville, CA
• Serge Plamondon · Russell, CA
• Roger Remillard · Napierville, CA
• Margaret E. Sorenson · Swedesburg, US
• Yasutsugu Ueda · Clinton, US
• Michael A. Walker · Durham, US

Key dates

• Filing date: Aug 16, 2006
• Grant date: Mar 31, 2009
• Expiry date: Feb 8, 2027

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention encompasses a series of bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.